Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Outcomes following first-line therapy in routine clinical practice in ALCL

Nicolas Martinez-Calle • 14 May 2020
Lymphoma Brentuximab vedotin

Nicolas Martinez-Calle, MD, MSc, Nottingham University Hospitals NHS Trust, Nottingham, UK, discusses outcomes following first-line therapy in routine clinical practice in ALCL in the UK. These data were submitted as an abstract to the BSH 2020 meeting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nicolas Martinez-Calle

3:17
Treating CLL in the UK: current and future outlooks
Nicolas Martinez-Calle • 11 Jun 2023
2:40
EPIC update: observational study of first-line acalabrutinib treatment for CLL
Nicolas Martinez-Calle • 11 Jun 2023
9:35
Outcomes of older patients with primary CNS lymphoma
Nicolas Martinez-Calle • 14 May 2020
1:14
CLL: IgHV mutational status
Nicolas Martinez-Calle • 21 Sep 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals